6,28 Clinically, GLP-1 RAs are indicated for the treatment of type 2 diabetes (all) and obesity (liraglutide and semaglutide only) and have beneficial effects on patient-important outcomes such as weight loss, cardiovascular and kidney events, hepatic steatosis, and mortality
These are primarily indicated for type 2 diabetes management rather than obesity treatment, though they may contribute to modest weight loss
Physical activity helps improve insulin sensitivity and aids in weight loss, complementing the effects of semaglutide
Your prescribing clinician will determine the appropriate monitoring schedule based on your individual medical history and risk profile
Disclaimer: These statements are for informational purposes only and have not been evaluated by the Food and Drug Administration
And the sooner you understand those pathways, the sooner you can stop blaming yourself for feeling weaker in the gym